Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibikase Therapeutics, Inc.IKT · Entity 5838 | Director | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibikase Therapeutics, Inc.
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2036-06-26 | Direct | 155,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 155,000 · Balance 155,000 F1: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RayzeBio, Inc.
Report date February 26, 2024 · Filed February 27, 2024
Section 16 reporting ended · disclosed 2024-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 1
1 source rowRow 1 · 2024-02-26 · Disposition to issuer · Disposed 78,433 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount. F2: Includes 876 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on February 22, 2024. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2031-12-14 | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-26 · Disposition to issuer · Disposed 301,745 · Balance 0 F3: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2032-11-30 | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-26 · Disposition to issuer · Disposed 149,777 · Balance 0 F3: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.72 · Expires 2033-11-16 | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-26 · Disposition to issuer · Disposed 164,000 · Balance 0 F3: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount.
F2: Includes 876 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on February 22, 2024.
F3: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 30, 2026 20:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001193125-26-290475 · ownership.xml · derivative · entry 1 Kush Arvind · CIK 0001986806 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2036-06-26 F1 · derivative.exercise_date: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 23:41 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 108,176 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0000950170-25-093430 · ownership.xml · derivative · entry 1 Kush Arvind · CIK 0001986806 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,176 Underlying: Common Stock · 108,176 shares Expires 2032-06-30 F1 · derivative.exercise_date: The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:19 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 116,585 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0000950170-25-023595 · ownership.xml · derivative · entry 2 Kush Arvind · CIK 0001986806 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,585 Underlying: Common Stock · 116,585 shares Expires 2035-02-14 F2 · derivative.exercise_date: The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:19 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 56,600 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0000950170-25-023595 · ownership.xml · derivative · entry 1 Kush Arvind · CIK 0001986806 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,600 Underlying: Common Stock · 56,600 shares Expires 2035-02-14 F1 · derivative.exercise_date: The options vested and became exercisable on February 14, 2025. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 23:49 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0000950170-24-116783 · ownership.xml · derivative · entry 2 Kush Arvind · CIK 0001986806 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-10-21 F1 · derivative.exercise_date: The option shares vest 50% on each of the first two anniversaries of October 21, 2024. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 23:49 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | PurchaseCommon Stock | 145,000 | $1.37 | $198,650.00 |
DisclosureSEC source: 0000950170-24-116783 · ownership.xml · nonDerivative · entry 1 Kush Arvind · CIK 0001986806 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,000 Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 16:42 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 164,000 | Not disclosed Strike: $22.72 | Not disclosed |
DisclosureSEC source: 0001415889-24-005502 · form4-02272024_090236.xml · derivative · entry 4 Kush Arvind · CIK 0001986806 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 164,000 shares Expires 2033-11-16 F3 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 16:42 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 149,777 | Not disclosed Strike: $3.24 | Not disclosed |
DisclosureSEC source: 0001415889-24-005502 · form4-02272024_090236.xml · derivative · entry 3 Kush Arvind · CIK 0001986806 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 149,777 shares Expires 2032-11-30 F3 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 16:42 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 301,745 | Not disclosed Strike: $3.24 | Not disclosed |
DisclosureSEC source: 0001415889-24-005502 · form4-02272024_090236.xml · derivative · entry 2 Kush Arvind · CIK 0001986806 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 301,745 shares Expires 2031-12-14 F3 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $62.50 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 16:42 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerCommon Stock | 78,433 | $62.50 | $4,902,062.50 |
DisclosureSEC source: 0001415889-24-005502 · form4-02272024_090236.xml · nonDerivative · entry 1 Kush Arvind · CIK 0001986806 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount. F2 · shares: Includes 876 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on February 22, 2024. Read SEC document |
| November 17, 2023 Filed Nov 17, 2023 18:38 UTC | RayzeBio, Inc. RYZB · Entity 93779 | GrantStock Option (right to buy) · Derivative | 164,000 | $0.00 Strike: $22.72 | $0.00 |
DisclosureSEC source: 0001628280-23-039538 · wk-form4_1700264308.xml · derivative · entry 1 Kush Arvind · CIK 0001986806 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,000 Underlying: Common Stock · 164,000 shares Expires 2033-11-16 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments over the four-year period measured from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.